KCT0007327招募中未知
Randomized Phase 3 Trial Comparing Upfront Surgery versus Neoadjuvant modified FOLFIRINOX in Patients with Resectable Pancreatic Cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 314
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. The subject may provide signed subject consent, including compliance with the requirements and restrictions described in the Informed Consent Form (ICF) and this clinical trial protocol.
- •2. From at least 19 years of age inclusive, at study entry.
- •3. Has cytological or histological confirmed diagnosis of pancreatic cancer.
- •4. participant with resectable pancreatic cancer according to NCCN criteria without prior chemotherapy (determined by CT, MRI, or PET-CT results, borderline resectable pancreatic cancer is not included)
- •5. Have a performance status of 0 or 1 on the ECOG performance scale
- •6. weight > 30 kg
- •7. Normal organ and bone marrow function
- •- platelet = 100 x 109/L, Absolute neutrophil count = 1.5 x 109/L and emoglobin > 9 g/dL(Blood transfusion is allowed if it is 7 days before screening)
- •- Creatinine <1.5 x ULN
- •- Total bililubin = 2 x ULN
- •- ALT and AST = 2.5 x
- •8. The subject is willing and able to comply with the clinical test protocol during the trial period, including administration and scheduled visits and examinations, including follow-up.
- •9. The subject has no non-melanoma skin cancer, cervical intraepithelial carcinoma, localized prostate cancer, papillary thyroid cancer, or other malignant disease, except for all other cancers that have been previously treated for the purpose of cure for more than 5 years without evidence of recurrence.
排除标准
- •1. has a medical or psychiatric condition that threatens participant’s ability to provide consent or to comply with the protocol, or a history of non-compliance.
- •2. has an obstructed gastrointestinal tract.
- •3. has active gastrointestinal bleeding.
- •4. has had a myocardial infarction within 6 months prior to administration of the test drug and has other clinically significant heart disease(unstable angina, congestive heart failure or uncontrolled hypertension)
- •5. has the opinion that participant’s participation in the test is undesirable or has a rationale of severe or uncontrolled systemic disease or pathogenesis that threatens protocol compliance.
- •6. adenosquamous carcinoma and neuroendocrine tumor are excluded
- •7. has a history of another primary malignancy except for the following.
- •a. was treated for curative purpose, had no known active disease for at least 5 years prior to the first IP administration, and has a malignant tumor with a low potential risk for recurrence.
- •b. had no evidence of disease and had properly treated nonmelanoma skin cancer or malignant melanoma.
- •c. had no evidence of disease and had properly treated carcinoma in situ.
- •d. had no evidence of disease and had properly treated prostate cancer or papillary thyroid carcinoma
- •8. is pregnant or breastfeeding, or (male or female) has no intention to use effective contraception from screening to 6 months after the last administration of chemotherapy after surgery.
- •9. is known to be allergic or hypersensitive to any of the test drugs or to any of the test drug additives.
- •10. judges him/herself that participant is not suitable for his/her participation in the study and it is unlikely that participant will comply with the test procedures, restrictions and requirements.
- •11. is being administered prohibited drugs according to domestic approvals.
- •12. has an active infection requiring systemic therapy.
- •13. has had or is currently suffering from uncontrolled HIV, hepatitis B (HBV DNA < 2000 IU/mL can be registered for chronic hepatitis B or HBV carrier) or hepatitis C.
研究者
相似试验
已完成
3 期
Randomized Phase III Trial Comparing surgery-alone to UFT+PSK in Stage II Rectal CancerRectal cancerJPRN-UMIN000001527Japanese Foundation for Multidisciplinary Treatment of Cancer540
已完成
3 期
Randomized phase III trial of surgery followed by mFOLFOX6 as adjuvant chemotherapy versus peri-operative mFOLFOX6 plus cetuximab for KRAS wild type resectable liver metastases of colorectal cancerResectable colorectal liver metastasesJPRN-UMIN000007787Hepato-biliary-pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo500
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to imatinib mesylateGastro-intestinal stromal tumour (GIST)Cancer - Other cancer typesACTRN12609000681257European Organisation for Research and Treatment of Cancer (EORTC)350
尚未招募
3 期
A phase III randomized study evaluating surgery of residual disease in patients with metastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.bowel wall cancer1001799010017998GISTNL-OMON32805European Organisation for Research in Treatment of Cancer (EORTC)60
进行中（未招募）
不适用
A phase III randomized study evaluating surgery of residual disease in patients withmetastatic gastro-intestinal stromal tumor responding to Imatinib mesylate.EUCTR2007-002257-23-GBEuropean Organization for Research and Treatment of Cancer350